

Application No. 09/986,234
Response dated November 3, 2005
Responsive to Office Action dated August 3, 2005

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-9 (Canceled).

10 (Currently amended): The method of claim 34, wherein said ~~mammalian~~ resistin polypeptide has ~~the shares at least about 30% sequence identity with an~~ amino acid sequence of SEQ ID NO:2.

11 (Currently amended): The method of claim 34, wherein said ~~mammalian~~ resistin polypeptide has ~~the shares at least about 30% sequence identity with an~~ amino acid sequence of SEQ ID NO:4.

12-22 (Canceled).

23 (Currently amended): The method of claim 34, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, ~~and a synthetic antibody, a humanized antibody, and an antibody selected from a phage display library.~~

24 (Previously presented): The method of claim 34, wherein said composition further comprises a pharmaceutically-acceptable carrier.

Application No. 09/986,234
Response dated November 3, 2005
Responsive to Office Action dated August 3, 2005

25-33 (Canceled).

34 (Currently amended): A method of treating or alleviating type 2 diabetes, said method comprising administering to a patient afflicted with type 2 diabetes an amount sufficient to reduce serum glucose of a composition comprising an antibody that specifically binds a resistin polypeptide selected from the group consisting of a resistin polypeptide having the amino acid sequence of SEQ ID NO:2 and a resistin polypeptide having the amino acid sequence of SEQ ID NO:4~~with a mammalian resistin polypeptide, or fragment thereof, and a pharmaceutically acceptable carrier.~~

35-83 (Canceled).